SSRI treatment during pregnancy: Are we asking the right questions?

Depression and Anxiety

Volumn 27, Issue 8, 2010, Pages 695-698

  Wisner, Katherine L ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

COGNITIVE THERAPY; CONCEPTION; DEPRESSION; DRUG SAFETY; GESTATIONAL DEPRESSION; HEALTH CARE POLICY; HUMAN; MAJOR DEPRESSION; MEDICAL ETHICS; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PSYCHOTHERAPY; PUBLIC HEALTH; PUERPERAL DEPRESSION; REVIEW;

ABNORMALITIES, DRUG-INDUCED; ANTIDEPRESSIVE AGENTS; CROSS-SECTIONAL STUDIES; DEPRESSIVE DISORDER, MAJOR; DRUG UTILIZATION; FEMALE; HUMANS; INCIDENCE; INFANT, NEWBORN; NEONATAL ABSTINENCE SYNDROME; ODDS RATIO; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; SEROTONIN UPTAKE INHIBITORS; UNITED STATES;

EID: 77956864182     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20729     Document Type: Review

References (20)

1. Chambers C, Moses-Kolko E, Wisner K. Antidepressant use in pregnancy: New concerns, old dilemmas. Expert Rev Neurother 2007;7:761-764.
2. Gaynes B, Gavin N, Meltzer-Brody S, et al. Perinatal depression: Prevalence, screening accuracy, and screening outcomes. Evidence Report/Technology Assessment No. 119. (Prepared by the RTI-University of North Carolina Evidence-based Practice Center, under Contract No. 290-02-0016.) AHRQ Publication No. 05-E006-2. Rockville, MD: Agency for Healthcare Research and Quality; 2005.
3. Reefhuis J, Rasmussen S, Friedman J. Selective serotoninreuptake inhibitors and persistent pulmonary hypertension of the newborn. NEJM 2006;354:2188-2190.
4. Andrade S, Gurwitz J, Davis R, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004;191:298e407.
5. Vesga-Lopez O, Blanco C, Keyes K, et al. Psychiatric disorders in pregnancy and postpartum women in the United States. Arch Gen Psychiatry 2008;65:805-815.
6. Bonari L, Pinto N, Ahn E, et al. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004;49:726-735. (Pubitemid 40100521)
7. Yonkers K, Wisner K, Stewart D, et al. The management of depression during pregnancy: A report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009;31:403-413.
8. Murray L, Cooper P. Postpartum depression and child development. Psychiatry Med 1997;27:253-260.
9. Deave T, Heron J, Evans J, Emond A. The impact of maternal depression in pregnancy on early child development. BJOG 2008;115:1043-1051.
10. Bonari L, Koren G, Einarson T, et al. Use of antidepressants by pregnant women: Evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making. Arch Women Ment Health 2005;8:214-220.
11. Cohen L, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006;295: 499-507. (Pubitemid 43200344)
12. Wisner K, Sit D, Hanusa B, et al. Major depression and antidepressant treatment: Impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009;166:557-566.
13. Stothard K, Tennant P, Bell R, Rankin J. Maternal overweight and obesity and the risk of congenital anomalies: A systematic review and meta-analysis. JAMA 2009;301:636-650.
14. Alwan S, Reefhuis J, Rasmussen S, et al. National birth defects prevention S. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. NEJM 2007;356: 2684-2692.
15. Louik C, Lin A, Werler M, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. NEJM 2007;356:2675-2683.
16. Greene M. Teratogenicity of SSRIs-serious concern or much ado about little? NEJM 2007;356:2732-2733.
17. Salisbury AL. Prenatal Depression and SSRI Impact on Offspring Development. Presented at American College of Neuropsychiatry annual meeting, Session 231, December, 2009.
18. Andrade S, McPhillips H, Loren D, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009;18:246-252.
19. Pederson L, Henriksen T, Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 2010;125:e600-e608.
20. Sit D, Perel J, Helsel J, Wisner, K. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry 2008;69:652-658.